By combining JAK2 inhibitors with other targeted therapies, such as inhibitors of BCL-2 (to promote apoptosis) or FLT3 inhibitors (to block additional tyrosine kinase signaling), it is possible to simultaneously target multiple signaling pathways that drive leukemia. Here, JAK2 is linked to leukemia.